Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson'sPRNewsWire • 07/01/21
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical TrialPRNewsWire • 06/23/21
Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative DisorderBenzinga • 04/21/21
Alterity to present at the 7th International Congress of Multiple System AtrophyPRNewsWire • 02/26/21
Alterity Therapeutics Ltd (ATHE) CEO David Stamler on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Alterity Therapeutics stock more than doubles on massive volume after new patent announcementMarket Watch • 11/16/20
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseasesPRNewsWire • 11/16/20
Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson'sMarket Watch • 08/04/20
Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA DrugBenzinga • 08/04/20